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Abstract 
 
Background: Ziwan Baibu Tang (ZBT) is used as a traditional Chinese prescription used in the clinic to cure a variety of respiratory 
diseases. The objective of this study was to evaluate the acute and subacute toxicity of ZBT. 
Materials and Methods: Fifty Kunming mice were assigned to 5 groups, and ZBT was administered at different concentrations. 
Symptoms, mortality and behavioural changes were recorded. Eighty Wistar rats were randomly allocated to 4 treatment groups or a 
control group for 4 weeks of treatment (half male and half female); general observations and weekly body weight (BW) gain were 
recorded. At the end of the 4-week experiment, the rats were sacrificed, and blood was collected for haematological and serum 
biochemical analyses. Samples from the primary organs were fixed in 10% buffered formalin for histopathological studies. 
Results: The calculated LD50 of acute oral toxicity was 319.16 g/kg BW. After the 4-week treatment, BW did not significantly differ 
in any of the dose groups, compared with the control group (P>0.05), and the rat blood red blood cell (RBC) and haemoglobin (HGB) 
levels in each dose group did not significantly differ (P>0.05). In addition, serum urea and creatine levels in each dose group did not 
significantly differ from those in the control group (P>0.05).  
Conclusion: These results indicate that ZBT does not possess toxic potential and that both the acute and subchronic toxicity in 
animals are very low. 
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Introduction 
 
Herbs and herbal preparations have been used to treat disease throughout human history. According to World Health 
Organization (WHO) statistics, 70–80% of the world’s population employs plant-derived traditional treatment methods for health 
problems (Ahmad et al., 2006; Shirwaikar et al., 2009). Traditional Chinese medicine (TCM) has been used in China for thousands 
of years to diagnose and treat diseases (Chou et al., 2008). TCM theories are based on syndrome differentiation and holistic medicine. 
Chinese herbal medicine (CHM), the pharmaceutical and most important component of the TCM system, combines compounds in 
the form of processed natural products (Li et al., 2013) and is supported by extensive literature and clinical applications covering 
thousands of years (Xu et al., 2009). A compound formulation is prescribed according to the principle, “Monarch, Minister, Assistant 
and Guide.” A formulation that contains more than two Chinese herbs conforms more closely to TCM theories and better reflects the 
characteristics of TCM than the administration of a single herb (Jiao et al., 2004). Studies of the effects of CHM formulas are 
attracting increasing attention globally (Shi et al., 2011). 
Ziwan Baibu Tang (ZBT) is a traditional Chinese prescription that is now used in the clinic to cure a variety of respiratory 
diseases, such as pneumonia, respiratory tract infections, cough and phlegm (Cheng et al., 2014). ZBT consists of 7 crude drugs: 
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Aster Tataricus, Stemona Japonica, Platycodon Grandiflorus, Cortex Mori, Herba Houttuyniae, Folium Eriobotryae and Glycyrrhiza. 
Aster Tataricus is the chief component in this prescription and is clinically used to eliminate phlegm and relieve cough in China. 
Aster Tataricus also possesses diuretic, antibacterial, antitumour, antiviral and anti-ulcer activities (Hou et al., 2006). Herba 
Houttuyniae is commonly used in TCM and provides antiviral, anti-inflammatory, antibacterial, and heat-clearing properties for the 
treatment of pneumonia and throat swelling; it has also been shown to increase the immune response in vivo and in vitro (Chen et al., 
2014). Stemona Japonica (Zhu et al., 2010), Platycodon Grandiflorus (Song et al., 2006), Cortex Mori (Feng et al., 2004), Folium 
Eriobotryae (Ju et al., 2003) and Glycyrrhiza (Tian et al., 2006) are used traditionally as medicinal herbs for the treatment of 
respiratory tract infections in China, and several research studies have revealed that these herbs provide respiratory therapeutic 
effects (Chinese Pharmacopoeia Commission, 2010).  
The safety of ZBT is generally assumed from its very long history of consumption in China. However, the consumption of 
plants and plant products whose content, toxicity profile and safe dose have not been determined may cause severe toxicity problems 
in humans and animals. Despite knowledge of the biological activities of ZBT, toxicological and side effect profiles have not been 
adequately documented. To provide scientific data for clinical drug safety, the present study investigated the acute and subchronic 
oral toxicity of ZBT by applying the recommended guidelines for safety or dose-dependent toxicity in mice and rats.  
 
 
Materials and Methods 
Instruments and Reagents 
 
A haematology analyser (SYSMEX, pocH-100iV, Japan), thin semiautomatic microtome (Leica RM 2265), organization 
stand/dryer (Leica HI 1210), and automatic biochemistry analyser (Mindray Biomedical) were used. An aspartate aminotransferase 
kit (AST, 150211009), alanine aminotransferase kit (ALT, 150111013), albumin kits (ALB, 150909014), creatinine reagent kit 
(Creatinine, 151011012), urea kits (Urea, 151311013) and a creatine kinase kit (CK, 152511010) were provided by Mindray 
Biomedical Co., Ltd. 
 
Preparation of ZBT Extract 
 
ZBT consists of 7 crude drugs; the plant components and their origins are listed in Table 1. Briefly, a mixture of 150 g of Aster 
Tataricus, 150 g of Stemona Japonica, 120 g of Platycodon Grandiflorus, 120 g of Cortex Mori, 180 g of Herba Houttuyniae, 150 g 
of Folium Eriobotryae and 130 g of Glycyrrhiza was macerated with 12,000 mL of distilled water for 2 h and decocted at 100 °C for 
1.5 h. The filtrate was collected, and the residue was again decocted for 1.5 h in 10,000 mL of distilled water. The extracts were 
combined and further condensed at 65 °C to obtain the aqueous extract of ZBT (1000 mL). 
 
Table 1: The composition of ZBT 
 
Species Chinese name Plant components Origin Grams(g) % 
Aster Tataricus Zi wan Root, stem Hebei, China 150 15 
Stemona Japonica Bai bu Root Jiangxi, China 150 15 
Platycodon Grandiflorus Jie geng Root Liaoning, China 120 12 
Cortex Mori Sang bai pi Rhizodermis Henan, China 120 12 
Herba Houttuyniae Yu xing cao Whole herb Sichuan, China 180 18 
Folium Eriobotryae Pi pa ye Leaves Zhejiang, China 150 15 
Glycyrrhiza Gan cao Root, stem Xinjiang, China 130 13 
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Animals 
 
Young mice weighing 18-22 g were purchased from the Animal Physiology Laboratory of Lanzhou University. Adult female 
and male Wistar rats (aged two months, weighing 181-199 and 185-205 g, resp.) were supplied by the production facility of the 
Animal Physiology Laboratory, Gansu University of Traditional Chinese Medicine (Gansu, China). The accession number was 
GTCM-150823. The animals were fed in a separate room with a barrier system under a controlled light-dark cycle (12-12 h, lights 
on 7:00-19:00), ventilation (air exchange rate of 18 cycles/h), temperature (23±2 °C) and relative humidity (55±15%) during the 
study. The cages and chip bedding were changed twice each week (Wang et al., 2011). The experiments were initiated after 
acclimatizing the rats for 1 week. The study was performed in accordance with Veterinary Laboratory Biosafety Guidelines (The 
Chinese Ministry of Agriculture Guide, 2003). 
 
Acute Oral Toxicity Study in Mice 
 
Fifty healthy Kunming mice (equal numbers of males and females, 18-22 g) were randomly assigned to 5 groups. ZBT was 
dissolved at different concentrations in distilled water and administered to the Kunming mice via oral gavage at doses of 250.00, 
300.00, 360.00, 432.00, and 518.40 g/kg body weight (BW) per day. All mice were fasted overnight to eliminate food from the 
gastrointestinal tract before dosing. After gavage, the mice were observed for 14 days to observe their symptoms, mortality, 
behavioural changes, skin, eyes, fur and somatic motor activity. Finally, the LD50 was calculated using Bliss software. 
 
Subchronic Oral Toxicity Test in Rats 
 
Eighty Wistar rats were assigned to 4 groups (high-dose group, medium-dose group, low-dose group, and control group; 20 rats 
in each group, half male and female). The treated groups received ZBT at a dose of approximately 10/LD50, 50/LD50 and 100/LD50 
every day, and the control group received an equal dose of physiological saline between 9:00 a.m. and midnight every day for 4 
weeks. The general observations for clinical signs included behavioural changes, signs of gross toxicity, fur condition and somatic 
motor activity. The animals were weighed on the first day of administration, and the individual BWs of the rats were recorded every 
subsequent week. The mean weekly BW gain was calculated for each sex and measured weekly. The rats were allowed unlimited 
access to food throughout the study. 
At the end of the 4-week experiment, the animals were fasted for 12 h and then sacrificed by decapitation under anaesthesia 
with sodium pentobarbital (30 mg.kg−1) intraperitoneally administered. Blood was collected in two tubes: tube 1, containing EDTA, 
was processed immediately for haematological parameters; tube 2, without additive, was centrifuged at 3000×g at 4 °C for 10 min to 
obtain serum (stored at -20 °C until analysis). The organs (heart, liver, spleen, lungs and kidneys) were weighed, and the absolute 
organ weights were converted to relative organ weights based on the organ-to-BW ratio. Organ samples were fixed in 10% formalin 
for histopathological examination.  
 
Haematological and Serum Biochemical Analysis 
 
Haematology indexes were detected by pocH-100iV (haematology analyser and reagent) and included the white blood cell 
(WBC), red blood cell (RBC) and platelet (PLT) counts, as well as the haemoglobin (HGB) measurement. The following 
measurements were obtained: alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT, albumin (ALB), 
creatine kinase (CK) and urea. 
 
 
Histopathological Studies 
 
After weighing the collected organs, all samples were fixed in 10% buffered formalin. In the histological analysis, we assessed 
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the tissue integrity of the organs and observed the presence of degeneration, necrosis, leukocyte infiltration, congestion, blood 
extravasation or fibrosis. 
 
Statistical Analysis 
 
The LD50 was calculated using the Bliss method. The data for weekly BW, relative organ weights, haematology and serum 
biochemistry were evaluated by one-way ANOVA using SPSS 17.0 statistical software. All values are expressed as the mean±SD. P 
values less than 0.05 were considered significant. 
 
 
Results 
Acute Oral Toxicity 
 
After administration of ZBT, the mice in the high-dose group lay quietly and rarely moved. In addition, the mice exhibited 
reduced spontaneous activity and slow movement. Few mice developed movement disorders, shortness of breath or obvious 
neurological symptoms. As the dose of ZBT increased, the symptoms intensified. Prior to death, the mice exhibited symptoms such 
as hind limb twitching, disordered hair coat and difficulty breathing. After 7 d, the surviving mice exhibited good appetite, improved 
vitality and normal movement. The hair coat of the surviving mice became smooth and shiny. Death mainly occurred within 1-2 h 
following oral gavage of ZBT. The mice were dissected and examined. The following major organ lesions were observed: duodenal 
haemorrhage, liver darkening and inconspicuous bleeding and bruising. No significant gross lesions were detected in other organs. 
As shown in Table 2, 0, 4, 9, 9 and 10 deaths were respectively observed in the 5 groups of mice within 7 d after administration of 
ZBT. The LD50 of ZBT in mice and the 95% confidence limits were calculated by the Bliss method using SPSS 13.0 software. The 
LD50 was 319.16 g/kg BW, and the 95% confidence interval was 270.31–363.68 g/kg BW. 
 
Table 2: Mortality of the mice in the acute toxicity experiment 
Group Dose (g/kg BW) Number of mice Mortality 
1 250.00 10 0 
2 300.00 10 4 
3 360.00 10 9 
4 432.00 10 9 
5 518.40 10 10 
 
Observation of Gross Toxicity and Mortality 
 
Experimental observations of the rats indicated that there were no abnormal changes in the experimental groups or control 
group in terms of food intake, water intake, mental state, respiratory condition, and coat gloss or body temperature. No rats died 
during the experimental period. 
 
Body Weight Changes and Organ Weights 
 
As shown in Tables 3 and 4, during the experimental period, there were no significant differences in BW between the control 
group and the groups of rats that received different doses of ZBT (P>0.05). Compared with the control group, female rats in the 
low-dose group exhibited significantly decreased heart weight/BW coefficient (P<0.05). By contrast, no significant differences in 
the heart weight/BW coefficient were observed between the rest of the groups and the control group (P>0.05). In addition, there 
were no significant differences between the control group and the various dose groups in the organ weight/BW coefficients of the 
liver, spleen, lung and kidney (P>0.05). 
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Haematology 
 
The haematological profiles of the treated and control groups are presented in Table 5. After continuous dosing for 4 weeks, 
WBC levels decreased significantly (P<0.05) in females in the high-dose group compared with the control group, and PLT levels 
significantly decreased (P<0.05) in both sexes in the high-dose group. No significant differences in RBC and HGB levels were 
observed in the dose groups (P>0.05).  
 
 
Table 3: Weekly body weight gain in subchronic oral administration test 
Groups 1 week 2 weeks 3 weeks 4 weeks 
Female     
Vehicle 188.05±7.52 203.55±5.12 217.78±6.77 232.07±6.49 
3 g/kg BW 188.10±6.91 201.15±5.35 215.50±6.96 230.00±7.22 
15 g/kg BW 185.50±8.63 200.75±8.18 214.82±9.50 230.20±8.82 
30 g/kg BW 182.65±5.43 194.47±5.79 205.44±6.99 217.06±7.11 
Male     
Vehicle 202.87±9.34 218.10±8.43 235.11±7.98 251.96±8.08 
3 g/kg BW 200.02±5.63 216.23±6.03 232.42±6.45 247.10±7.51 
15 g/kg BW 199.84±10.09 214.58±9.79 229.33±10.09 243.09±9.89 
30 g/kg BW 197.55±6.67 209.41±7.00 221.74±7.16 232.90±8.01 
Values are means±SEM for 20 rats in each group, half male and half female.  
 
Table 4: Effects of subchronic oral administration on relative organ weights 
Group Heart Liver Spleen Lung Kidney 
Female      
Vehicle 0.68±0.02 6.39±0.66 0.37±0.01 1.01±0.03 0.51±0.01 
3 g/kg BW 0.62±0.02 6.47±0.83 0.35±0.01 0.96±0.03 0.48±0.01 
15 g/kg BW 0.62±0.02 6.71±0.91 0.34±0.01 0.95±0.03 0.48±0.01 
30 g/kg BW 0.58±0.02* 6.25±0.66 0.36±0.01 0.96±0.02 0.48±0.01 
Male      
Vehicle 0.69±0.02 6.56±0.83 0..41±0.01 1.12±0.04 0.55±0.01 
3 g/kg BW 0.68±0.02 6.78±0.75 0.40±0.01 1.06±0.03 0.54±0.01 
15 g/kg BW 0.69±0.03 6.65±0.88 0.39±0.01 1.15±0.04 0.53±0.01 
30 g/kg BW 0.69±0.02 6.43±0.56 0.40±0.01 1.10±0.03 0.53±0.01 
Values are means±SEM for 20 rats in each group, half male and half female. Statistically significant compared to controls (*P<0.05).
  
 
Serum Chemistry 
 
After 4 weeks of continuous administration of ZBT, no significant differences in urea levels were observed in the control group 
and the various groups of rats that received different doses of ZBT (P>0.05). In addition, there were no significant differences in 
serum creatinine levels between the control group and the low-dose group or between the control group and the moderate-dose group 
(P>0.05). Compared with the control group, female rats in the high-dose group exhibited significantly decreased serum ALB levels 
(P<0.05). Serum ALB levels were also markedly reduced in male rats in the moderate-dose group and high-dose group compared to 
the control group (P<0.05). No significant differences in serum AST activity were detected between the control group and various 
dose groups (P>0.05). Compared with the control group, male rats in the moderate-dose group exhibited significantly elevated CK 
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activity (P<0.05). By contrast, there were no significant differences in CK activity between the control group and the low-dose or 
high-dose group (P>0.05). No dose-response relationship between serum CK activity and ZBT dose was observed (Table 6). 
 
Table 5: Haematological parameters in Wistar rats treated orally with ZBT for 4 weeks 
Group WBC/(×109 · L-1) RBC/(×1012 · L-1) HGB/g · L-1) PLT/(×109 · L-1) 
Female     
Vehicle 13.59±2.89 8.41±2.14 171.38±23.04 420.88±60.63 
3 g/kg BW 12.53±2.48 8.56±2.13 172.69±21.19 441.47±65.21 
15 g/kg BW 11.98±3.99 8.24±1.27 168.53±43.90 524.56±56.78 
30 g/kg BW 10.43±2.89* 8.60±1.09 175.71±19.73 596.50±74.15* 
Male     
Vehicle 10.73±0.68 9.78±1.12 177.64±13.33 232.08±56.28 
3 g/kg BW 8.84±0.43 8.34±2.14 170.87±24.02 257.87±88.71 
15 g/kg BW 10.69±0.64 8.18±1.16 166.00±25.29 279.13±46.42 
30 g/kg BW 9.29±0.64 7.86±2.13 158.44±21.32 384.27±62.07* 
Values are means±SEM for 20 rats in each group, half male and half female. Statistically significant compared to controls *P<0.05, 
**P<0.01. 
 
 Table 6: Serum biochemistry in Wistar rats treated orally with ZBT for 4 weeks 
Group AST (U/L) AST/ALT ALB (g/L) 
Urea 
(mmol/L) 
Creatinine 
(μmol/L) 
CK 
(μmol/L) 
Female       
Vehicle 318.50±19.07 2.61±0.15 34.04±0.25 7.13±0.28 73.83±2.52 5373.67±198.71 
3 g/kg BW 358.63±16.52 3.06±0.11 34.21±0.29 6.99±0.22 70.71±1.21 4570.75±379.30 
15 g/kg BW 241.88±19.28 2.37±0.15 33.59±0.37 7.14±0.14 70.88±1.67 4811.88±394.28 
30 g/kg BW 246.10±11.29 2.69±0.15 30.94±0.26* 6.04±0.29 62.20±1.07 4777.80±296.45 
Male       
Vehicle 239.25±7.17 2.22±0.11 35.10±0.14 6.67±0.26 80.33±1.65 3704.44±504.07 
3 g/kg BW 268.14±26.44 2.13±0.17 34.34±0.28 7.69±0.27 72.88±1.44 3539.88±497.87 
15 g/kg BW 284.71±23.26 2.25±0.12 33.14±0.33* 6.26±0.26 69.29±1.80 5297.57±306.58* 
30 g/kg BW 199.50±3.77 1.82±0.20 33.93±0.61* 6.54±0.34 68.40±2.40 3260.50±700.20 
Values are means±SEM for 20 rats in each group, half male and half female. Statistically significant compared to controls *P<0.05, 
**P<0.01. 
  
Discussion 
 
Safety studies of plants and plant products and establishing the effectiveness and safety of plants and plant products via 
scientific research are increasingly emphasized. The complexity of herbal preparations and their natural biological variations 
requires their safety, effectiveness and quality to be established (Shin et al., 2011; Lee et al., 2012). ZBT is a traditional Chinese 
prescription that is used in clinical practice. ZBT was developed by modifying Zi Wan San, an ancient medical prescription collected 
in "Tai Ping Sheng Hui Fang" (The Peaceful Holy Benevolent Prescriptions). ZBT consists of 7 Chinese herbs, including Aster 
Tataricus, Stemona Japonica, Platycodon Grandiflorus and Cortex Mori. Aster Tataricus relieves cough and asthma, clears away 
lung-heat, moistens intestines and relaxes bowels (Hou et al., 2006). Cortex Mori purges the lung of pathogenic fire, relieves the 
symptoms of asthma and induces diuresis to alleviate oedema (Feng et al., 2004). Herba Houttuyniae opens inhibited lung-energy, 
stops coughing and clears away heat and toxic substances (Chen et al., 2014). Glycyrrhiza uralensis expels phlegm, stops coughing, 
relieves acute symptoms, removes toxic substances and coordinates the effects of various drugs in the prescription (Tian et al., 2006). 
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Therefore, ZBT produces effects such as relief of cough and asthma, heat clearing and detoxification. In addition, as natural 
medicines, TCMs possess unique advantages, including anti-stress activity, improvement of nonspecific immunity and regulation of 
metabolism. Combined with these unique advantages, ZBT exhibits good clinical effectiveness in the treatment of bronchial asthma, 
phlegm-heat panting and cough. 
 
Histopathology 
 
In the histological investigation, organs including the heart, liver, spleen, lung and kidney exhibited no sign of pathological 
changes compared with the corresponding organs in the control group (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Histopathological photomicrographs obtained at 4 weeks 
Liver 200×, Heart 400×, Spleen 200××, Lung 200×, Kidney 200× 
 
There were no significant differences in BW between rats in the control group and the groups exposed to different doses of ZBT 
during the experimental period (P>0.05). However, the BW of the rats in the various dose groups decreased in a dose-dependent 
manner, indicating that high doses of ZBT impact the appetite of rats. Increasing the dose of ZBT may have reduced food intake by 
the rats. Consequently, the control group exhibited greater weight gain, but the effect of ZBT on BW was not significant. Compared 
with the control group, female rats in the high-dose group exhibited a markedly reduced heart weight/BW coefficient (P<0.05). By 
contrast, no significant differences in the heart weight/BW coefficient were detected between the control group and the low- or 
moderate-dose group (P>0.05). The coefficient of organ weight/BW is a crucial detection index in the evaluation of drug safety and 
provides a quantitative reference for drug evaluation. However, it is impossible to identify changes in organs based on the 
coefficients alone (Yuan et al., 2003). Combining these coefficients with the results of a series of blood biochemical indices in the 
, I. S., Yu, Y. , I. S., Yu, Y. 
C. S., 2011. 
Subchronic 
of Sipjeipje 
 Xin et al., Afr J Tradit Complement Altern Med. (2016) 13(3):140-149 
   http://dx.doi.org/10.4314/ajtcam.v13i3.17 
9. 
147 
 
 
rats revealed no significant differences in AST and CK between the control group and various dose groups (P>0.05). 
Histopathological examination of heart tissue sections from the rats in the various dose groups revealed no abnormalities, indicating 
that ZBT had little effect on the hearts of female rats at doses of less than 30 g/kg BW. 
The haematopoietic system can serve as an indicator of toxic effects because of its sensitivity to toxic compounds (Adeneve et 
al., 2006). Compared to the control group, the groups that received different doses of ZBT exhibited varying decreases in WBC 
levels in the blood. Among the ingredients of ZBT, the medicinal herb Aster tataricus contains shionone, a type of flavonoid. 
Shionone promotes S-phase (the phase of DNA synthesis) entry in mouse Kupffer cells and significantly increases the number of 
cells in the mitotic phase, indicating that shionone is capable of promoting the proliferation of liver Kupffer cells and activating the 
function of Kupffer cells. In addition, shionone significantly promotes the phagocytic activity of lung macrophages and peritoneal 
macrophages (Li et al., 1991). In the present study, no gross abnormalities were detected in various organs and tissues by 
histopathological examination. Therefore, ZBT does not appear to affect WBCs in the blood of rats. During the experimental period, 
blood PLT counts were significantly increased in both female rats and male rats exposed to high doses of ZBT compared with the 
control group. This result is consistent with findings by Chen et al. that adrenocortical hormones stimulate the haematopoietic 
activity of bone marrow and may increase the number of platelets (Chen et al., 2003). Compared to the control group, the male rats 
in the various dose groups exhibited significantly decreased blood RBC and HGB levels (P>0.05). One of the components of ZBT, 
Glycyrrhiza uralensis, contains enoxolone. The adrenocortical hormone-like activity of enoxolone likely initiates negative feedback 
regulation in vivo, thereby inhibiting the production of RBC and HGB. The specific mechanism remains to be further investigated. 
The results of the present study indicate that ZBT had little effect on the WBC, RBC, HGB and PLT levels in the blood of rats. 
Most drugs cause liver damage during transformation in the liver. The extent of damage is related to the dosage and 
concentration of the drugs. Liver damage often leads to increased ALT and AST activity and elevated ALB content (Wang et al., 
2010). However, because the increases in AST and ALT were not necessarily parallel and transaminase activity only reflects liver 
disease activity, the AST/ALT ratio is used as an index to evaluate liver health. The AST/ALT ratio is a highly sensitive index and 
accurately reflects the degree of liver damage and prognosis (Wang et al., 2001). Urea and creatinine are two indices commonly used 
to evaluate renal function. Under normal conditions, the production and excretion of urea and creatinine are in a state of dynamic 
equilibrium. However, when the kidney undergoes pathological changes, serum urea and creatinine levels significantly change. AST 
and CK are abundantly expressed in the myocardium. Under normal conditions, the activities of AST and CK are very low in the 
serum. When the myocardial tissue is injured, cell permeability increases. Large amounts of AST and CK enter the blood, resulting 
in significantly increased AST and CK activities. Serum AST and CK measurements exhibit high sensitivity and specificity and are 
recognized as the "gold standard" for the detection of cardiomyocyte damage (Meng et al., 2005). 
Most drugs cause liver damage during transformation in the liver. The extent of damage is related to the dosage and 
concentration of the drugs. Liver damage often leads to increased ALT and AST activity and elevated ALB content (Wang et al., 
2010). However, because the increases in AST and ALT were not necessarily parallel and transaminase activity only reflects liver 
disease activity, the AST/ALT ratio is used as an index to evaluate liver health. The AST/ALT ratio is a highly sensitive index and 
accurately reflects the degree of liver damage and prognosis (Wang et al., 2001). Urea and creatinine are two indices commonly used 
to evaluate renal function. Under normal conditions, the production and excretion of urea and creatinine are in a state of dynamic 
equilibrium. However, when the kidney undergoes pathological changes, serum urea and creatinine levels significantly change. AST 
and CK are abundantly expressed in the myocardium. Under normal conditions, the activities of AST and CK are very low in the 
serum. When the myocardial tissue is injured, cell permeability increases. Large amounts of AST and CK enter the blood, resulting 
in significantly increased AST and CK activities. Serum AST and CK measurements exhibit high sensitivity and specificity and are 
recognized as the "gold standard" for the detection of cardiomyocyte damage (Meng et al., 2005). 
After administration of ZBT for 4 weeks, serum ALB levels did not significantly differ between the control group and female 
rats in the low-dose group or moderate-dose group (P>0.05). By contrast, serum ALB levels were significantly reduced in the 
high-dose group compared with the control group (P<0.05). However, there were no significant differences in the AST/ALT ratio 
between the control group and the various dose groups (P>0.05). These results indicate that ZBT did not cause liver damage in the 
female rats. Urea levels in the female and male rats that received various doses of ZBT did not significantly differ from those in the 
control group (P>0.05). In addition, creatinine levels did not significantly differ between the control group and the various dose 
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groups (P>0.05). These results indicate that 4 weeks of continuous administration of ZBT had little effect on the kidney in rats. 
Compared with the control group, the high-dose group exhibited markedly reduced serum AST levels (P<0.05). However, CK 
content did not significantly differ among the groups (P>0.05). The combined experimental results indicate that ZBT did not induce 
myocardial injury in the female rats. Serum ALB levels indicated that compared to the control group, 4 weeks of continuous 
administration of ZBT did not cause liver damage in rats. CK levels were drastically increased in the moderate-dose group compared 
to the control group (P<0.05). However, there were no significant differences in serum AST activity between the control group and 
the low-, moderate- or high-dose groups (P>0.05). The above results suggest that ZBT had little effect on the rat myocardium. 
 
Conclusion 
 
The results of the present study demonstrate that the oral administration of ZBT has no significant impact on rat organs. After 4 
weeks of continuous administration, the high-dose group (30 g/kg BW) was exposed to ZBT at a level far exceeding the 
recommended dosage in clinical applications. Therefore, ZBT should be considered an effective and highly safe Chinese herb 
medicine suitable for long-term clinical application. 
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